DUBLIN--(BUSINESS WIRE)--The "Uveitis - Market Insights, Epidemiology and Market Forecasts to 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
Uveitis market is expected to grow during the forecasted period of 2018-2027 owing to the launch of nine drugs (presently in Phase III).
Uveitis Therapeutics market has seen a global sales of 5.4 billion in 2016. The three best selling drugs were Vimpat (UCB), Lamictal (Glaxosmithkline) and Keppra (UCB) with Vimpat recording highest sales of 895 million in 2016.
According to research, the prevalent cases of Uveitis was 706,666 in 2016 in 7MM, of which 643,721 cases were of Non-Infectious Uveitis (NIU). United States account for highest prevalent cases of Uveitis with 392,035 prevalent cases in 2016 followed by France.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Uveitis from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
The disease epidemiology covers the prevalence of both Infectious and Non-Infectious Uveitis (NIU). Prevalence of NIU is further segmented into four types basis of sub-type [Intermediate Uveitis, Pan-Uveitis, Posterior Uveitis, Anterior noninfectious uveitis (aNIU] in 7MM.
Key Topics Covered:
1. Report Introduction
2. Uveitis Market Overview at a Glance
3. Uveitis: Overview
4. Epidemiology and Patient Population
5. Treatment Algorithm
6. Current Unmet Needs of Uveitis
7. Marketed Drugs
8. Emerging Drugs Analysis
9. Market Size of Uveitis in 7MM
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fc83qv/global_uveitis?w=4